Business
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Oversubscribed Financing led by Coastlands Capital with participation from new and existing inves...
About this update from Canadian Goldcamps Corp
[{"type":"text","content":"CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders\n\n\n\n\n Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors\n \n\n\n\n Financing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of proceeds to fund the Phase 1/2 clinical trial in patients with SYNGAP1-related disorders, expected to initiate as early as 2H 2026\n \n\n\n\n Doug Williams, Ph.D., to become Board Chair, and Dan Tardiff, Ph.D., elevated to Chief Scientific Officer\n \n\n\n CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) --\n \n CAMP4 Therapeutics Corporation\n \n (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors for up to $100 million in gross proceeds through a private placement. CAMP4 intends to use the net proceeds from the private placement to fund the preclinical and clinical development of its SYNGAP1 program, working capital, and general corporate purposes.\n \n\n “With this financing we are well positioned to bring a potential first-in-class treatment for SYNGAP1-related disorders into the clinic,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “This investment marks a critical milestone as we continue our mission of developing potentially disease modifying medicines for patients with disorders marked by suboptimal gene expression.”\n \n\n The private placement is comprised of an initial upfront financing of $50 million in gross proceeds in exchange for 26,681,053 shares of common stock priced at $1.53 per share of common stock sold at the initial closing, 36,361 shares of common stock priced at $1.65 to certain directors, employees and consultants of CAMP4 at the initial closing, and 6,003,758 pre-funded warrants in lieu of common stock for $1.5299 for each pre-funded warrant sold in lieu of common stock at the initial closing. ...